Anabolic agents for osteoporosis not clearly better than zoledronic acid: ICER analysis
Access to the full content of this site is available only to registered healthcare professionals.
Register to read more
The Institute for Clinical and Economic Review (ICER) found no evidence that either abaloparatide (Tymlos) or teriparatide (Forteo) had superior efficacy vs the other or vs zoledronic acid in preventing postmenopausal vertebral fracture.
Why this matters
Patients’ adherence to antiresorptive agents is poor, and new options are needed.
Although clinically effective, the 2 anabolic antiosteoporotic drugs are expensive, and it is unclear if either is better.
The assessors did a network meta-analysis of pivotal trials of abaloparatide and teriparatide, the 2 FDA-approved anabolic agents for postmenopausal women with osteoporosis at high risk for fracture.
They also calculated cost-effectiveness of both drugs.
They also summarized trial results of romosozumab (Evenity), a third anabolic agent now being reviewed by the FDA.